Swiss biotech firm halts trial of heart drug

11/8/2004 | Bloomberg

Actelion plans to tell investors today that it stopped the phase III clinical trial of Veletri, a proposed treatment for acute heart failure, because the study failed to show effectiveness. The study's steering committee recommended stopping the trial because 1,300 patients showed no statistically significant results. No safety issues surfaced in the trial, the firm said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ